SynergyMed

SynergyMed is a C-Corp medical device company based in the United States. Currently, the company has 14 employees. SynergyMed develops cancer treatment products for human, veterinary, and research applications using a noninvasive ablation technology. Their technology platform can be used as an alternative to surgery for early-stage breast, head & neck, skin, and lung cancers and for pain relief in palliative care treatments. This technology precisely and effectively ablates and destroys cancer tumors without harming surrounding healthy tissues. The system utilizes specialized noninvasive electromagnetic applicators, FDA/CE approved nanoparticles placed within the tumor, and proprietary algorithms that optimize the ablation process while tracking temperature and measuring treatment dose. The company's technology has been tested in mice with successful results and is undergoing trials with dogs for the veterinary market. SynergyMed also plans to begin first-in-human clinical trials. SynergyMed is seeking venture capital funding and strategic partnerships. The company accepts pre-orders for their devices for research and development as well as veterinary applications.